Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.

Diabetes Obes Metab · 2025 · PMC12515751 · PMID 40891155

Europe PMC DOI

hedged sentence

0.1120

closest p · 2.2× alpha

0.1120

boldest claim

The sentences

did not reach statistical significancep = 0.112not close (p > 0.1)

The ≥10% group showed a numerical improvement that did not reach statistical significance ( p = 0.112).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.